MX2020007681A - Terapia de combinacion para tratar o prevenir el cancer. - Google Patents

Terapia de combinacion para tratar o prevenir el cancer.

Info

Publication number
MX2020007681A
MX2020007681A MX2020007681A MX2020007681A MX2020007681A MX 2020007681 A MX2020007681 A MX 2020007681A MX 2020007681 A MX2020007681 A MX 2020007681A MX 2020007681 A MX2020007681 A MX 2020007681A MX 2020007681 A MX2020007681 A MX 2020007681A
Authority
MX
Mexico
Prior art keywords
treating
combination therapy
preventing cancer
cancer
preventing
Prior art date
Application number
MX2020007681A
Other languages
English (en)
Inventor
Alexander Stevenson
Original Assignee
4D Pharma Res Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1800927.4A external-priority patent/GB201800927D0/en
Priority claimed from GBGB1801502.4A external-priority patent/GB201801502D0/en
Priority claimed from GBGB1805941.0A external-priority patent/GB201805941D0/en
Priority claimed from GBGB1806572.2A external-priority patent/GB201806572D0/en
Priority claimed from GBGB1808636.3A external-priority patent/GB201808636D0/en
Application filed by 4D Pharma Res Limited filed Critical 4D Pharma Res Limited
Publication of MX2020007681A publication Critical patent/MX2020007681A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La invención provee una terapia de combinación que comprende una cepa bacteriana para el tratamiento y la prevención del cáncer.
MX2020007681A 2018-01-19 2019-01-18 Terapia de combinacion para tratar o prevenir el cancer. MX2020007681A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB1800927.4A GB201800927D0 (en) 2018-01-19 2018-01-19 Combination therapy for treating or preventing cancer
GBGB1801502.4A GB201801502D0 (en) 2018-01-30 2018-01-30 Combination therapy for treating or preventing cancer
GBGB1805941.0A GB201805941D0 (en) 2018-04-10 2018-04-10 Combination therapy for treating or preventing cancer
GBGB1806572.2A GB201806572D0 (en) 2018-04-23 2018-04-23 Combination therapy for treating or preventing cancer
GBGB1808636.3A GB201808636D0 (en) 2018-05-25 2018-05-25 Combination therapy for treating or preventing cancer
PCT/GB2019/050142 WO2019141997A1 (en) 2018-01-19 2019-01-18 Combination therapy for treating or preventing cancer

Publications (1)

Publication Number Publication Date
MX2020007681A true MX2020007681A (es) 2020-09-14

Family

ID=65278397

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007681A MX2020007681A (es) 2018-01-19 2019-01-18 Terapia de combinacion para tratar o prevenir el cancer.

Country Status (14)

Country Link
US (1) US20210060093A1 (es)
EP (1) EP3740219A1 (es)
JP (1) JP2021510688A (es)
KR (1) KR20200110341A (es)
CN (1) CN111629740A (es)
AU (1) AU2019210003A1 (es)
BR (1) BR112020014595A2 (es)
CA (1) CA3088333A1 (es)
IL (1) IL275860A (es)
MA (1) MA51614A (es)
MX (1) MX2020007681A (es)
SG (1) SG11202006870XA (es)
TW (1) TW201938179A (es)
WO (1) WO2019141997A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023072968A1 (en) * 2021-10-25 2023-05-04 4D Pharma Research Ltd Compositions comprising bacterial strains

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
ES2895666T3 (es) 2006-10-27 2022-02-22 Capsugel Belgium Nv Cápsulas duras de hidroxipropilmetilcelulosa y proceso de fabricación
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
CA2987129A1 (en) * 2015-06-01 2016-12-08 The University Of Chicago Treatment of cancer by manipulation of commensal microflora
MA41013B1 (fr) * 2015-11-20 2018-07-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41708A (fr) * 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes

Also Published As

Publication number Publication date
IL275860A (en) 2020-08-31
CA3088333A1 (en) 2019-07-25
BR112020014595A2 (pt) 2020-12-08
US20210060093A1 (en) 2021-03-04
AU2019210003A1 (en) 2020-07-30
SG11202006870XA (en) 2020-08-28
CN111629740A (zh) 2020-09-04
WO2019141997A1 (en) 2019-07-25
MA51614A (fr) 2021-04-28
TW201938179A (zh) 2019-10-01
EP3740219A1 (en) 2020-11-25
KR20200110341A (ko) 2020-09-23
JP2021510688A (ja) 2021-04-30

Similar Documents

Publication Publication Date Title
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
PH12020551080A1 (en) Combination therapy for treating or preventing cancer
MX2020003770A (es) Terapias de combinacion para tratar cancer.
MD3600363T2 (ro) Compoziții cuprinzând tulpini bacteriene
EA201991818A1 (ru) Лечение рака
MX2020009736A (es) Composiciones que comprenden cepas bacterianas.
MX2021003903A (es) Terapia combinada para el melanoma.
MX2020008195A (es) Compuestos para el tratamiento del dolor.
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
PH12021550102A1 (en) Cardiosafe antidiabetic therapy
MD3638271T2 (ro) Compoziții cuprizând tulpini bacteriene
WO2018183692A8 (en) VECTORS AND COMPOSITIONS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
MX2021009670A (es) Tratamiento para el cancer.
MX2020007664A (es) Terapia de combinacion para tratar o prevenir el cancer.
MX2020007681A (es) Terapia de combinacion para tratar o prevenir el cancer.
MX2020007665A (es) Terapia de combinacion para tratar o prevenir el cancer.
MX2020012964A (es) Metodos para el tratamiento de cancer de vejiga.
MX2021013908A (es) Tratamiento para el cáncer.
EA202091730A1 (ru) Комбинированная терапия для лечения или профилактики рака
EA202091636A1 (ru) Комбинированная терапия для лечения или профилактики рака
EA202091635A1 (ru) Комбинированная терапия для лечения или профилактики рака
MX2019009199A (es) Composiciones y métodos para modular ppp2r1a.
GB201808636D0 (en) Combination therapy for treating or preventing cancer
MX2021013776A (es) Composiciones que comprenden cepas bacterianas.